[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "https://identifiers.org/MONDO:0005086"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/PUBCHEM.COMPOUND:9823820"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "lenvima is a kinase inhibitor that is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodine refractory differentiated thyroid cancer dtc 1 1 in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior anti angiogenic therapy 1 2 for the first line treatment of patients with unresectable hepatocellular carcinoma hcc 1 3 lenvima is indicated for the treatment of patients with locally recurrent or metastatic progressive radioactive iodine refractory differentiated thyroid cancer dtc lenvima is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma rcc following one prior anti angiogenic therapy lenvima is indicated for the first line treatment of patients with unresectable hepatocellular carcinoma hcc"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/MONDO:0005086",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "https://identifiers.org/PUBCHEM.COMPOUND:9823820",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-06-08T21:07:15.752+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "Ezal1yShsdnUhXEdC18GfpnE+yHuPlwTyuABdgUVHVto70HYiXHROyx4dJpUEmMzAiqTtbpwWw7h2+dZXsXFfbi5VqsniqoP0EkqAqcqeb2zZ1THzvHennGbjdZ2Vrx/XE5XgLgBIvoVL29cej/vNUGURpQvqIydw9ISZREkDs8="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A"
    } ]
  } ],
  "@id" : "http://purl.org/np/RACdNXEXMZgWLxg-5rSlzFB_5bA7riKOE-2N5PyLDay8A#pubinfo"
} ]